<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782781</url>
  </required_header>
  <id_info>
    <org_study_id>LIA-AH-1</org_study_id>
    <nct_id>NCT01782781</nct_id>
  </id_info>
  <brief_title>Local Infiltration Analgesia After Abdominal Hysterectomy</brief_title>
  <acronym>LIA</acronym>
  <official_title>Local Infiltration Analgesia After Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <authority>Sweden: Swedish Data Inspection Board</authority>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate traditional analgesic therapy after abdominal
      hysterectomy with single infiltration of local anesthetics in the surgical area at the end
      of surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a controlled, double blind, prospective, randomized and performed at
      Sahlgrenska University Hospital in Goteborg, Sweden. The injectant mixture consists of 300
      mg ropivacaine mixed with 30 mg ketorolac and 0.5 mg epinephrine. Total volume of the
      solution is 156 ml. The normal saline injection is used in the control group in the same
      manner as in the LIA group. The parameters which would be evaluated are consumption of
      morphine, pain intensity and side effects.

      The primary objective is to evaluate whether local infiltration analgesia (LIA) into the
      operating field will reduce morphine consumption during the first 24 postoperative hours in
      patients undergoing abdominal hysterectomy (AH).

      Secondary end-points are pain intensity, incidence of nausea and vomiting, sedation
      intensity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity (NRS, Numeric Rating Score 0-10)</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea and vomiting</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation intensity (Ramsey scale)</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group P (Placebo) receives a local infiltration of  saline in the operating field and ketorolac iv.
In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (Active) receives a local infiltration of  ropivacaine, ketorolac and epinephrine in the operating field and saline iv.
Drug: ropivacaine, ketorelac and epinephrine
In Group A the injectant mixture consists of ropivacaine 300 mg  mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine, ketorelac and epinephrine</intervention_name>
    <description>Active group</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Narop, Toradol and adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring abdominal hysterectomy

        Exclusion Criteria:

          -  BMI &gt; 35

          -  ASA &gt; 3

          -  Renal dysfunction

          -  Allergic to ASA

          -  Unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Egron Thorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anil Gupta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Orebro University Hospital, Orebro, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ove Carlsson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Olausson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olof Eckre, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven-Erik Ricksten, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma Backman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Gynecological Surgery, Orebro University Hospital, Orebro, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Stadberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Gynecological Surgery, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven-Egron Thorn, MD PhD</last_name>
    <phone>+46313434903</phone>
    <email>sven-egron.thorn@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Hayden, MD</last_name>
    <phone>+46313430716</phone>
    <email>jane.hayden@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Gynecological Surgery and Anesthesia and Intensive Care, Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <zip>SE41385</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven-Egron Thorn, MD, PhD</last_name>
      <phone>+46313434903</phone>
      <email>sven-egron@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Jane Hayden, MD</last_name>
      <phone>+46313430716</phone>
      <email>jane.haydenvg@region.se</email>
    </contact_backup>
    <investigator>
      <last_name>Sven-Egron Thorn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Local infiltration analgesia</keyword>
  <keyword>Pain, relief</keyword>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Adrenergic Agonists</keyword>
  <keyword>Sympathomimetics</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Analgesics, Non-Narcotic</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Opioids</keyword>
  <keyword>Morphine</keyword>
  <keyword>Pain</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Anesthetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
